2006
DOI: 10.1002/cncr.22334
|View full text |Cite
|
Sign up to set email alerts
|

Phase II study of intravenous TZT‐1027 in patients with advanced or metastatic soft‐tissue sarcomas with prior exposure to anthracycline‐based chemotherapy

Abstract: Auditory information is important for social and reproductive behaviors in birds generally, but is crucial for oscine species (songbirds), in particular because in these species auditory feedback ensures the learning and accurate maintenance of song. While there is considerable information on the auditory projections through the forebrain of songbirds, there is no information available for projections through the brainstem. At the latter levels the prevalent model of auditory processing in birds derives from a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
29
0
3

Year Published

2007
2007
2014
2014

Publication Types

Select...
5
3
1

Relationship

0
9

Authors

Journals

citations
Cited by 58 publications
(35 citation statements)
references
References 122 publications
(177 reference statements)
3
29
0
3
Order By: Relevance
“…When administered to patients with advanced non-small cell lung cancer, who had previously received treatment with platinum-based chemotherapy, TZT-1027 demonstrated no anti-cancer activity [194]. Similarly, although TZT-1027 was found to be safe and well tolerated when given to 29 patients with advanced or metastatic softtissue sarcomas, no objective response was observed and the most commonly reported toxicities were neutropenia, fatigue, and constipation [195]. Lastly, three phase I trials have been conducted to set the MTD of ABT-751, a novel orally bioavailable sulphonamide.…”
Section: Vascular-disrupting Mtasmentioning
confidence: 99%
“…When administered to patients with advanced non-small cell lung cancer, who had previously received treatment with platinum-based chemotherapy, TZT-1027 demonstrated no anti-cancer activity [194]. Similarly, although TZT-1027 was found to be safe and well tolerated when given to 29 patients with advanced or metastatic softtissue sarcomas, no objective response was observed and the most commonly reported toxicities were neutropenia, fatigue, and constipation [195]. Lastly, three phase I trials have been conducted to set the MTD of ABT-751, a novel orally bioavailable sulphonamide.…”
Section: Vascular-disrupting Mtasmentioning
confidence: 99%
“…Due to the promising data from phase I studies of TZT-1027 against soft tissue sarcoma, phase II trials were conducted in patients with advanced or metastatic soft tissue sarcomas. Phase II study revealed that TZT-1027 was safe and well tolerated (Patel et al 2006). However, in another phase II study conducted on patients with advanced nonsmall-cell lung cancer after treatment with platinum-based chemotherapy, TZT-1027 was found inactive as an anticancer drug (Riely et al 2007).…”
Section: Microtubule Disruptorsmentioning
confidence: 99%
“…These favorable results have resulted in TZT-1027 reaching Phase II clinical trials stage for different types of cancer (Patel et al, 2006;Riely et al, 2007).…”
Section: Dolastatins: From Deception To Hope Through Structural Modifmentioning
confidence: 99%